Deprenyl Tablets 5mg (DepPro)

What is DepPro?

Deprenyl (Selegiline Hydrochloride), branded as DepPro, is a selective monoamine oxidase-B (MAO-B) inhibitor available for purchase for research purposes. Initially studied for its impact on neurological conditions, Deprenyl has been researched for its potential regulation of neurotransmitters such as dopamine.

Please note, this product is not FDA-approved for treating or curing any specific condition, and any therapeutic claims are based on ongoing research.

Note: A liquid dropper version is also available for research purposes.

Key Features

• Scored tablets for flexible measurement
• 50 tablets per box
• 2-3 weeks delivery
• Selegiline HCL for research
• Minimal excipients

Product Information

How it Works

Deprenyl is studied for its ability to selectively inhibit the MAO-B enzyme, which is involved in breaking down dopamine in laboratory models. Research investigates how MAO-B inhibition could impact dopamine levels, a neurotransmitter linked to various biological processes. These mechanisms remain under investigation and are primarily explored in experimental and research settings.

Research Use and Interactions

In laboratory settings, Deprenyl has demonstrated interactions with compounds affecting dopamine levels. Researchers should consult existing literature to understand potential interactions and conduct experiments accordingly. Studies also indicate that high-tyramine substances, such as aged cheese or cured meats, should be avoided in research using Deprenyl due to potential hypertensive reactions in in-vitro studies.

Chemical Properties

Potential Side Effects in Research

In research settings, Deprenyl may exhibit side effects, including headaches, dizziness, and insomnia. In rare cases, studies have noted more serious effects such as hypertensive reactions or serotonin syndrome when combined with certain compounds. Researchers should monitor experimental outcomes carefully and refer to existing literature for guidance.

Safety Information

DepPro is intended for research purposes only and should be used under proper laboratory conditions. Careful handling and adherence to safety protocols are essential when using this compound in experimental settings.

Storage Instructions

Store DepPro in a cool, dry place away from direct sunlight. Ensure the container is tightly sealed to protect the tablets from moisture and contamination, ensuring long-term stability for research use.

Regulatory Information

In the United States, Deprenyl may require a prescription for human consumption, but it is available for research purposes. In Australia and the European Union, regulations vary, so researchers should verify the legality of using Deprenyl in their region before purchase.

Packaging and Presentation

DepPro comes in a box containing 50 scored 5mg tablets. The tablets are designed for easy measurement in laboratory settings, and the box is sealed to protect the product from environmental factors.

Is DepPro Right for Your Research?

If you are conducting research into MAO-B inhibitors and require a stable, reliable source of Deprenyl, DepPro may be a suitable option for your studies. As with any research compound, ensure your protocols follow ethical and legal guidelines.

Frequently Asked Questions (FAQs)

Q: Can DepPro be combined with other compounds in research?

A: DepPro should not be combined with compounds affecting serotonin levels or high-tyramine substances without reviewing relevant literature to avoid interactions that may affect research outcomes.

Q: What is the proper storage for DepPro?

A: DepPro should be stored in a cool, dry place, away from direct sunlight. The container should be sealed tightly to protect it from moisture and contamination.

Q: Is DepPro legal for research purposes?

A: DepPro's legality varies by region. In the U.S., it may require a prescription for human use, but it is available for research purposes. Always verify local regulations before purchase.

References

• [1] Riederer P, Youdim MBH. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. J Neural Transm Suppl. 1986;22:209-15. Study Reference.
• [2] Knoll J. History of deprenyl - the first selective inhibitor of monoamine oxidase type B. Mech Ageing Dev. 2012;123(8):849-59. Study Reference.
• [3] Magyar K, Tihanyi K. The pharmacology of selegiline (deprenyl). Neuropsychopharmacology. 2004;29:11-21. Study Reference.

Disclaimer

This product is intended for research purposes only and is not designed for human consumption. Always consult relevant literature and follow legal guidelines when handling research compounds. This information is not intended as medical advice.